国: アメリカ合衆国
言語: 英語
ソース: NLM (National Library of Medicine)
CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: K3W1N8YP13) (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:K3W1N8YP13), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: IRH51QN26H) (CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:IRH51QN26H), BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) (UNII: QSN5XO8ZSU) (BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE IN
A-S Medication Solutions
INTRAMUSCULAR
BOOSTRIX is indicated for: • active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older, • immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. Do not administer BOOSTRIX to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of BOOSTRIX or after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine [see Description (11)] . Encephalopathy within 7 days of administration of a previous dose of a pertussis antigen-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis antigen-containing vaccine, including BOOSTRIX. Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to BOOSTRIX during pregnancy. Healthcare providers are encouraged to register women by calling
Product: 50090-1831 NDC: 50090-1831-9 .5 mL in a VIAL / 10 in a POUCH
Biologic Licensing Application
BOOSTRIX- TETANUS TOXOID, REDUCED DIPHTHERIA TOXOID AND ACELLULAR PERTUSSIS VACCINE, ADSORBED SUSPENSION A-S MEDICATION SOLUTIONS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BOOSTRIX SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BOOSTRIX. BOOSTRIX (TETANUS TOXOID, REDUCED DIPHTHERIA TOXOID AND ACELLULAR PERTUSSIS VACCINE, ADSORBED) INJECTABLE SUSPENSION, FOR INTRAMUSCULAR USE INITIAL U.S. APPROVAL: 2005 RECENT MAJOR CHANGES Indications and Usage (1) 10/2022 Dosage and Administration (2.2) 10/2022 INDICATIONS AND USAGE BOOSTRIX is a vaccine indicated for: • • DOSAGE AND ADMINISTRATION FOR INTRAMUSCULAR USE ONLY. • • • • DOSAGE FORMS AND STRENGTHS Single-dose vials and single-dose prefilled syringes containing a 0.5-mL suspension for injection. (3) CONTRAINDICATIONS • • WARNINGS AND PRECAUTIONS • • • • active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older, (1) immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. (1) Each dose of BOOSTRIX is administered as a 0.5-mL injection. (2.2) An initial dose of BOOSTRIX is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td). BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap). (2.2) BOOSTRIX may be administered for tetanus prophylaxis for wound management. For management of a tetanus-prone wound, a dose of BOOSTRIX may be administered if at least 5 years have elapsed since previous receipt of a tetanus toxoid-containing vaccine. (2.2) To provide protection against pertussis in infants younger than 2 months of age, administer BOOSTRIX during the third trimester of pregnancy. 完全なドキュメントを読む